PPIDT00189
Drug Information
| Name | Icatibant |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06196 |
| Type | biotech |
| Indication | Icatibant is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.[L49756] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
30 MG
|
| Injection, solution | Subcutaneous |
30.0 mg/3mL
|
| Solution | Subcutaneous |
10 mg / mL
|
| Solution | Subcutaneous |
3000000 mg
|
| Injection | Subcutaneous |
30 mg/3mL
|
| Injection, solution | Subcutaneous |
10 mg/1mL
|
| Injection, solution | Subcutaneous |
30 mg/3mL
|
| Injection, solution | Subcutaneous |
30 MG
|
| Injection, solution | — |
30 MG/3ML
|
| Solution | Subcutaneous |
30 mg / 3 mL
|
| Injection, solution | Parenteral |
30 mg
|
| Injection, solution | Parenteral |
30 mg/3ml
|
| Injection, solution | — |
30 MG
|